CivicaScript LLC, a Utah-based nonprofit company involved in bringing low-cost generic medicines to US patients, announced on Tuesday the availability of dimethyl fumarate delayed-release capsules.

Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

CivicaScript says that it will provides dimethyl fumarate 240 mg capsules for sale to pharmacies for USD47 per bottle of 60 capsules -- typically one month's supply. CivicaScript recommends that pharmacies charge patients no more than USD68 per bottle (CivicaScript's maximum retail price, or MaxRP).

CivicaScript claims that its MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label. CivicaScript will offer the 120 mg and 240 mg strengths of dimethyl fumarate capsules for sale.

According to CivicaScript, its MaxRP for dimethyl fumarate is approximately USD4,300 per month less than the average claim cost for prescriptions filled at traditional PBM-affiliated pharmacies. It could significantly reduce patients' out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines' price.

Dimethyl fumarate was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.